Radius Residential Care Valuation
Is RAD undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
4/6Valuation Score 4/6
Below Fair Value
Significantly Below Fair Value
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of RAD when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: RAD (NZ$0.23) is trading below our estimate of fair value (NZ$0.27)
Significantly Below Fair Value: RAD is trading below fair value, but not by a significant amount.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for RAD?
Key metric: As RAD is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.
| What is RAD's PS Ratio? | |
|---|---|
| PS Ratio | 0.4x |
| Sales | NZ$171.23m |
| Market Cap | NZ$64.11m |
| Key Statistics | |
|---|---|
| Enterprise Value/Revenue | 1.5x |
| Enterprise Value/EBITDA | 12.3x |
| PEG Ratio | n/a |
Price to Sales Ratio vs Peers
How does RAD's PS Ratio compare to its peers?
| Company | Forward PS | Estimated Growth | Market Cap |
|---|---|---|---|
| Peer Average | 4.6x | ||
PHL Promisia Healthcare | 0.8x | n/a | NZ$19.5m |
OCA Oceania Healthcare | 2.2x | 8.9% | NZ$579.4m |
ARV Arvida Group | 5.1x | n/a | NZ$1.2b |
SUM Summerset Group Holdings | 10.5x | 14.2% | NZ$3.1b |
RAD Radius Residential Care | 0.4x | 3.0% | NZ$64.1m |
Price-To-Sales vs Peers: RAD is good value based on its Price-To-Sales Ratio (0.4x) compared to the peer average (4.6x).
Price to Sales Ratio vs Industry
How does RAD's PS Ratio compare vs other companies in the Oceanian Healthcare Industry?
| 3 Companies | Price / Sales | Estimated Growth | Market Cap |
|---|---|---|---|
| 3 Companies | Estimated Growth | Market Cap | |
|---|---|---|---|
Price-To-Sales vs Industry: RAD is good value based on its Price-To-Sales Ratio (0.4x) compared to the Oceanic Healthcare industry average (1.5x).
Price to Sales Ratio vs Fair Ratio
What is RAD's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
| Fair Ratio | |
|---|---|
| Current PS Ratio | 0.4x |
| Fair PS Ratio | 1.2x |
Price-To-Sales vs Fair Ratio: RAD is good value based on its Price-To-Sales Ratio (0.4x) compared to the estimated Fair Price-To-Sales Ratio (1.2x).
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Analyst Forecast: Insufficient data to show price forecast.
Discover undervalued companies
Ryman Healthcare
NZ$3.4b
Develops, owns, and operates integrated retirement villages, rest homes, and hospitals for the elderly people in New Zealand and Australia.
RYM
NZ$5.00
7D
4.0%
1Y
-6.5%
EBOS Group
NZ$7.2b
Engages in the marketing, wholesale, and distribution of healthcare, medical, pharmaceutical, and animal care products in Australia, Southeast Asia, and New Zealand.
EBO
NZ$37.22
7D
0.05%
1Y
5.1%